ARID1A Biomarker Assessment for PLK1 Therapy Response Prediction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current Polo-like kinase 1 (PLK1) inhibiting therapies lack biomarkers to effectively predict responsiveness, leading to inefficiencies in patient stratification and treatment outcomes.

Innovation Solution

Determining the level and/or activity of AT-rich interacting domain 1A (ARID1A) in patient samples to predict responsiveness to PLK1 inhibiting therapies, using a combination of high-throughput detection assays and machine learning algorithms for accurate stratification and treatment prediction.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PLK1 inhibiting therapy is administered without biomarker-guided stratification, then treatment can be broadly applied to cancer patients, but treatment effectiveness is reduced due to inability to identify responsive patients

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidstratification complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent performs ARID1A biomarker assessment before administering PLK1 inhibiting therapy, enabling preliminary identification of patients likely to respond to treatment. This preliminary action ensures that only suitable patients receive the therapy, improving overall treatment effectiveness while avoiding unnecessary treatment of non-responders.

Inventive Principle:

Principle #10Preliminary action

2Measurement precision

If ARID1A biomarker assessment is implemented to predict responsiveness, then patient stratification accuracy is improved, but diagnostic complexity and cost increase

Engineering Contradiction:

Improveresponsiveness prediction accuracyVSAvoiddetection method complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent employs advanced detection technologies such as next-generation sequencing (NGS) and immunohistochemistry (IHC) to assess ARID1A biomarker status. These automated, high-throughput methods replace manual diagnostic approaches, improving measurement precision while managing complexity through standardized protocols and computational analysis.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Reliability

If biomarker testing is performed on all cancer patients, then responsiveness prediction is improved, but time to treatment initiation is extended

Engineering Contradiction:

Improvetreatment outcome predictionVSAvoidtime to treatment

Core Design Contradiction:

ReliabilityVSLoss of time

Solution Approach 1:

The patent integrates ARID1A biomarker assessment into the initial diagnostic workflow, performing the testing concurrently with other standard cancer workup procedures. This preliminary action allows treatment decisions to be made rapidly based on biomarker status, improving prediction reliability without significantly delaying treatment initiation.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20230416836A1Method for predicting responsiveness to PLK1 inhibition

Publication Date: 2023.12.28 NATIONAL UNIVERSITY OF SINGAPORE

AI summary

The present disclosure teaches a method of predicting the responsiveness of a subject towards a Polo-like kinase 1 (PLK1) inhibiting therapy. In one embodiment, there is provided a method for predicting the responsiveness of a subject towards a Polo-like kinase 1 (PLK1) inhibiting therapy, the method comprising determining the level and/or activity of AT-rich interacting domain 1A (ARID1A) in a sample obtained from the subject.